Story
Indian Equities Decline as IT and Consumer Stocks Weigh; Nifty 50 Hits 3-Month Low

Summary
India's benchmark stock indices closed lower on Tuesday, with the Nifty 50 falling to its lowest point in three months amid broad selling pressure led by the information technology and consumer durables sectors.
Indian equity markets ended Tuesday's session in negative territory, with benchmark indices declining amid broad-based selling pressure. The Nifty 50 index reached a new three-month low, reflecting sustained investor caution.
Closing Numbers
At the market close, the Nifty 50 fell 0.28%, while the BSE Sensex 30 registered a loss of 0.33%. The market breadth was negative, indicating widespread selling, as reported by exchange data.
- On the National Stock Exchange (NSE), 1,473 stocks declined compared to 1,139 that advanced.
- On the Bombay Stock Exchange (BSE), 2,239 stocks fell while 1,842 gained.
Sector and Stock Movers
The day's losses were primarily driven by weakness in the Consumer Durables, Real Estate, and Information Technology sectors. Titan Company Ltd (NSE:TITN) was a top laggard on the Nifty 50, falling 3.00%. Other significant decliners included Hero MotoCorp Ltd (NSE:HROM), down 2.60%, and IT major Wipro Ltd (NSE:WIPR), which dropped 2.33% to a five-year low.
AdBucking the downward trend were healthcare and infrastructure stocks. Dr Reddy’s Laboratories Ltd (NSE:REDY) was the top performer on the Nifty 50, gaining 2.53%. Adani Group stocks also showed strength, with Adani Enterprises Ltd (NSE:ADEL) rising 1.83% and Adani Ports and Special Economic Zone Ltd (NSE:APSE) up 1.40%.
Market Volatility and Commodities
Despite the decline in equity prices, the India VIX, a measure of the market's expectation of near-term volatility, fell by 2.05% to 13.36. This suggests that market participants may not be pricing in a significant increase in turbulence ahead.
In commodities, Gold Futures for December delivery saw a slight increase of 0.33%, while Crude oil for November delivery fell 0.42%. The US Dollar Index Futures, a gauge of the dollar's strength against a basket of currencies, was up 0.22%.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.